All posts by imreal

Better Butter Launches Line of Unique Whipped Blends of Organic cocoa, Shea & Coconut Butters to Enhance & Restore Skin’s Beauty


Better Butter Trio

“we saw a place where we could bring value to the growing number of people who want to treat their skin the way it deserves.”

There’s good news for people who are looking to enhance, restore, repair and improve their skin’s true beauty in a safe, harmless, chemical-free way. In exciting news, Better Butter has celebrated the launch of its brand of organic (naturally gluten free & vegan) whipped body butters, all made with the aim and intent to help users “love the skin they are in.” Currently, three amazing options are available. All feature natural oils and vitamins, with customizable options for different skin care goals. Customers have responded with enthusiasm.

“After years of working on and finally developing the right recipe of oils and vitamins to treat friends and family members with eczema, cellulite, darks spots and other skin issues, we saw a place where we could bring value to the growing number of people who want to treat their skin the way it deserves,” commented a spokesperson from Better Butter. “When compared with other brands, our products allow the big difference in your skin’s appearance to be seen much sooner when using our body butters daily. Even some serious skin problems, have drastically improved when customers use our product instead of some others on the market.”

The three organic (naturally gluten free & vegan) whipped body butters, available now from Better Butter, include Better Butter Basic, Better Butter Tropica’l, and Better Butter Zen.

Better Butter Basic is a unique blend of organic cocoa, shea and coconut butters with all-natural oils and vitamins.

Better Butter Tropica’l is a unique blend of organic mango, shea and coconut butters with all-natural oils and vitamins.

Better Butter Zen is the same as Basic, but it is also infused with natural white sage for its super relaxing properties that can strengthen focus and spiritual energy.

Special treatment options can be added to any of the three Better Butter options to meet these special needs:

  • exfoliation crystals
  • acne repair
  • dark spot / blemish / scar fader
  • stretch mark repair
  • and cellulite repair.

The feedback for the new brand has been quick, positive and passionate.

Maria K., recently said in a five-star review, “My skin has never felt so amazing. Applying the ‘Mars Cedar’ scented Better Butter, is like going on a mini vacation, every time.”

Sarah T., said in her five-star review, “Better Butter cleared up my toasted skin syndrome. My confidence level is through the roof. Now I can feel comfortable when I’m out with my friends this summer.”

The great reviews go on and on. With an amazingly affordable price, Better Butter is a brand poised to change the skin care game.

For more information be sure to visit https://www.shopbetterbutter.com.

About Better Butter

We create whipped organic body butter with a special blend of organic oils and vitamins. Our goal is to help our users, see the true beauty of their skin.

Media Contact

Michael Nelson

Media@ShopBetterButter.Com

646-301-3043

Instagram: abetter_butter

Share article on social media or email:

Thriveworks Counseling Comes to Arlington, VA—Now Open for Online Counseling


Thriveworks Counseling, a premium practice with 100+ locations around the country, opens its newest office in Arlington, VA. Thriveworks is now taking appointments for online counseling by phone and video.

In addition to online counseling, Thriveworks offers its clients unique benefits like their online booking system, innovative technologies, and flexible scheduling options. In addition to the normal daytime sessions, they offer clients evening and weekend sessions, too.

According to the Chief Compliance Officer at Thriveworks, Heidi Faust, their flexible scheduling options meet an important need: “In most cases, we find that prior to starting counseling at Thriveworks, our clients struggle to find providers who have availability during times that most working people are available, like evenings and weekends. Thriveworks addresses this problem.”

While Thriveworks Arlington is only open for online counseling as of now, they will offer in-person counseling sessions, too.

About Thriveworks:

Thriveworks Counseling connects clients with skilled, caring mental health professionals. These professionals can provide a range of mental health services, including but not limited to depression therapy, anxiety therapy, couples therapy, marriage counseling, and life coaching.

The Thriveworks team strives to fulfill their mission of helping people live happy, successful lives. To learn more about Thriveworks Arlington, call (703) 775-2939 or visit https://thriveworks.com/arlington-counseling/

Share article on social media or email:

Homeowners of America Insurance Company Announces Milestone


I want to express how grateful we are to have such an amazing group of agents…

Homeowners of America Insurance Company (HOAIC), a property and casualty insurance provider, has announced the noteworthy milestone of adding their two hundred thousandth customer to the company’s book of business as of June 25, 2020.    

In an internal announcement, Spence Tucker, President and CEO of HOAIC thanked his employees for making this happen and said, “This is an amazing accomplishment and you should be proud of your contribution. Reaching and maintaining this amount of customers has been made particularly difficult by the current pandemic but what we do is important. Our customers count on us to protect their most valuable assets.” Tucker also thanked HOAIC’s independent agent partners saying, “I want to express how grateful we are to have such an amazing group of agents to work alongside. This wouldn’t have been possible without you.”

Homeowners of America also has over two hundred million in premiums on the books and continues to grow as they write business through independent agent partnerships in six states with plans to add more in the near future.

About Homeowners of America Insurance Company

Homeowners of America Insurance Company (HOAIC) is based in Irving, Texas. The company provides property and casualty insurance in Texas, Arizona, Virginia, North Carolina, South Carolina, and Georgia and insures over 200,000 homes. HOAIC has been assigned a Financial Stability Rating of A, Exceptional by Demotech, Inc. For more information, visit https://hoaic.com.

Share article on social media or email:

TPx Taps 25-Year Telecom Veteran Ken McMahon as SVP of Customer Success


Ken McMahon, SVP of Customer Success, TPx Communications

Ken McMahon, SVP of Customer Success, TPx Communications

“Ken is both a competitive leader and powerful advocate for the customer. As such, he’s highly qualified to lead the launch of the TPx customer success organization.”

TPx Communications, the premier managed services provider, today announced that telecom industry veteran Ken McMahon has joined the company in the newly created role of Senior Vice President of Customer Success, which makes customer centricity a strategic focus in TPx’s ongoing transformation.

In this key leadership position, McMahon will be responsible for building customer trust, ensuring customer satisfaction, driving service adoption and promoting retention. He will leverage many tools, including proactive engagement with customers as well as serving as their champion and liaison with other TPx organizations, such as marketing, product development, billing and technical support.

“Ken is both a competitive leader and powerful advocate for the customer. As such, he’s highly qualified to lead the launch of the TPx customer success organization,” said Greg Daily, Chief Revenue Officer at TPx. “Ken’s breadth and depth of executive experience will serve TPx well immediately and as it evolves to meet the ever-changing technology requirements of our business customers.”

McMahon has 25 years of experience leading various aspects of the end-to-end customer experience, including professional services, customer success, customer care, national operations and sales. He joins TPx from Vonage where he developed a Global Customer Success organization supporting unified communications as a service (UCaaS) and contact center as a service (CCaaS) customers. In this role, McMahon oversaw all customer implementations, care and technical support and customer success.

Previously, McMahon spent seven years at CenturyLink where he held a number of senior-leadership roles in sales, field operations and capital investment, among others. Prior to that, he was Director of Sales Support at EMBARQ, which was acquired by CenturyLink in 2009. Earlier, he held several roles managing customer care, support services and business transformation for Sprint.

“During my career I’ve led organizations in sales, operations, care and technical support, service delivery, customer success, marketing and more,” said McMahon. “Along the way, I’ve been involved in eight mergers and acquisitions, which means integrating and transforming organizations. I believe that the combination of business management experience, transformation experience, desire to drive value for customers and my competitive fire will benefit TPx.”

“I joined TPx because it has an excellent opportunity to accelerate growth with a large addressable market, great leadership, a strong product portfolio and a great partner in Siris Capital,” McMahon added. “This is a great opportunity and I want to be a part of the transformation to a best-in-class managed service provider.”

In February 2020, TPx was acquired by Siris Capital LLC, a leading private equity firm focused on investing and driving value creation in technology and telecommunications companies.

About TPx

Founded in 1998, TPx is a leading provider of UCaaS, Managed IT services and Managed Connectivity services, with approximately 25,000 customers with more than 50,000 customer locations across the U.S. TPx has best-in-class customer service embedded in its corporate DNA, offering guaranteed performance to all customers wherever there’s a broadband connection. TPx customers serve every business sector and include many government and not-for-profit enterprises. For more information, visit http://www.tpx.com or follow @TPxComm on Twitter.

Share article on social media or email:

Pinwheel Announces Integration with Wix, Enabling US-Based eCommerce Merchants to Sell CBD Products on Wix


We are excited about the growth opportunity in the burgeoning CBD industry and will continue to work with our acquiring banks and payment partners to support the industry as the regulatory framework for payment processing develops.

Pinwheel (PW), a licensed third-party payment provider with their own proprietary payment gateway, announced an integration with ecommerce platform, Wix. The affiliation allows US-based CBD merchants to process payments on Wix’s world-class website building platform.

Pinwheel is excited about their recent alliance with Wix. PW technology is now the bridge between a merchant’s ability to create a beautiful, customizable website as well as collecting payments within the environment created. PW’s simple, one-click integration into Wix’s platform provides CBD and other high-risk merchants the opportunity to process payments with stunning functionality.

The Pinwheel gateway is an agnostic platform designed to serve the needs of merchants in regulated industries often deemed “high risk” by the payment industry. Being platform agnostic means PW is compatible and adaptable to the Wix platform that merchants desire. PW is also proud to have helped thousands of merchants overcome complex challenges that traditional payment gateways and processors are unable or unwilling to tackle. In addition to the traditional features of a payment gateway, Pinwheel includes advanced features like transaction routing to multiple payment providers, 3DS functionality, multi-currency processing and conversion, and soon recurring payments.

“We are excited about the growth opportunity in the burgeoning CBD industry and will continue to work with our acquiring banks and payment partners to support the industry as the regulatory framework for payment processing develops,” says Blair Thomas, co-founder of Pinwheel.

Share article on social media or email:

Powering Exceptional Labs, A Bio-Rad Quality Control Virtual Conference, Gives Access to New Monthly Webinars Kicking Off, July 15, 2020


Powering Exceptional Labs, A Bio-Rad Quality Control Virtual Conference, Gives Access to New Monthly Webinars kicking off, July 15, 2020

Bio-Rad Laboratories, Inc. a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets, is bringing together industry leaders, collaborators, laboratory and medical professionals from around the world. As a leading global provider of in-vitro diagnostics supplies, our diagnostic products and systems leverage a broad range of technologies and deliver high-value clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions. Bio-Rad is the world leader in clinical quality control products, services, and information systems, products that ensure the accuracy and validity of clinical test results.

During the Quality Control Virtual Conference, attendees will be able to attend live webinars or view on-demand webinars presented by renowned speakers, covering a variety of important QC topics. Attendees can earn free P.A.C.E. CE credits by joining any of the webinars. New webinars will be released monthly, starting with Dr. Curtis Parvin, a Biostatistical Advisor presenting on the topic of “Best Practices in Quality Control: 10 Simple Recommendations” on July 15, 2020 at 11:00am PDT. Stay tuned for future webinar broadcast information.

Produced on LabRoots’ robust platform, this interactive environment with a poster hall that includes downloadable posters for scientists – by scientists, an exhibit hall with product booths that feature products, videos, brochures and infographics, allows attendees to connect seamlessly across all desktop and mobile devices and explore all that the event has to offer. This free online virtual conference will remain open around the clock through 2020, so stay up to date on the event page.

For more information or to register for the event, click here.

About Bio-Rad

Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers include university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality.

About LabRoots

LabRoots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.

Share article on social media or email:

A-Alpha Bio Awarded $800K to Develop Infectious Disease Drugs using AlphaSeq Platform


A-Alpha Bio

A-Alpha Bio

This approach will have broad implications for the development of therapeutics for highly diverse and newly emerging infectious diseases, including enteric bacterial pathogens and respiratory viruses like COVID-19.

A-Alpha Bio, a biotechnology startup that partners with pharmaceutical companies to accelerate drug development with multiplexed measurements of protein interactions, today announced that it had been awarded an $800,000 grant to optimize therapeutics for infectious diseases. Awarded by the Bill & Melinda Gates Foundation, the grant work will be carried out by A-Alpha Bio in partnership with Lumen Bioscience using machine learning models built from data generated by A-Alpha Bio’s proprietary AlphaSeq platform. A-Alpha Bio has already completed a pilot study in partnership with Lumen Biosciences and supported by the Gates Foundation. This pilot study successfully demonstrated the AlphaSeq platform’s ability to characterize binding of therapeutic antibodies against multiple pathogen strains simultaneously. With the latest grant, the companies will utilize AlphaSeq data to train machine learning models for the development of potent and cross-reactive therapeutics against intestinal and respiratory pathogens.

Intestinal and respiratory pathogens each cause an enormous global health burden. In developing countries, intestinal bacterial pathogens cause over 500,000 deaths per year in children under the age of 5. Repeated infections in young children lead to lifelong health problems, including developmental delays and cognitive impairment. Respiratory pathogens can be equally damaging, as demonstrated by the ongoing pandemic. As of July 9, more than 11.8 million cases of COVID-19 have been confirmed worldwide and more than 540,000 people have died.

When it comes to developing therapeutics to address these global health issues, one major challenge for both bacterial and viral pathogens is strain diversity. Small differences between closely related pathogens can render a therapeutic non-effective. Additionally, new pathogenic strains are continually emerging for which existing therapeutics are ineffective, requiring the constant development of new drugs. There is a critical need for drug development platforms to rapidly optimize antibodies for cross-reactivity against multiple pathogenic strains and for neutralization of emerging pathogens that pose a significant global health threat.

“Due to strain diversity, treating infections caused by enteric pathogens requires broadly cross-reactive drugs and COVID-19 has highlighted the necessity for a more rapid drug development pipeline. We are excited to collaborate with A-Alpha Bio and incorporate machine learning models to enhance and expedite antibody development” said Dr. Jim Roberts, CSO of Lumen Bioscience. “By enabling a higher throughput of antibody-antigen binding characterization, AlphaSeq, coupled with machine learning, can make a meaningful difference in the development of new drugs for many high-impact disease targets.”

AlphaSeq is a ‘multi-target’ antibody screening platform, enabling the measurement of millions of interactions between proteins with high quantitative accuracy. With continued support from the Bill & Melinda Gates Foundation, A-Alpha Bio will use AlphaSeq to measure binding between antibody candidates and multiple strain variants simultaneously in collaboration with Lumen Bioscience. AlphaSeq datasets will then be used to train machine learning models and predict antibody sequences likely to neutralize a broad diversity of pathogenic strains.

“We’re honored to have the continued support of the Bill & Melinda Gates Foundation as we pursue this exciting partnership with Lumen Bioscience to develop high-impact infectious disease therapeutics,” said Dr. David Younger, Co-Founder and CEO of A-Alpha Bio. “This next phase of our work with Lumen is happening at a critical time. Our hope is that by continuing to scale drug development capabilities through the AlphaSeq platform, we can accelerate the development of new, life-saving drugs for enteric and respiratory infectious diseases.”

Unlike existing platforms for characterizing many antibodies at once, AlphaSeq generates quantitative information about protein interactions and measures interactions in two-dimensions, examining all combinatorial interactions between many antibodies and many pathogen strains in one experiment. These properties make AlphaSeq particularly well suited for training machine learning models.

“The AlphaSeq platform outputs datasets that are perfectly suited for building ML models,” said Randolph Lopez, Co-Founder and CTO of A-Alpha Bio. Prior to the founding of A-Alpha Bio, Lopez worked at Microsoft Research on their DNA data storage project. His PhD concentrated on molecular neural nets. “By multiplying the power of AlphaSeq’s datasets through machine learning models, we will be able to scale protein testing even further and improve the prediction of antibody sequences with desired properties, including affinity, specificity, and cross-reactivity.”

The machine learning models developed through the partnership will be used to predict potent antibodies against novel pathogen strains and antibodies demonstrating cross-reactivity to multiple strains. If successful, this approach will have broad implications for the development of therapeutics for highly diverse and newly emerging infectious diseases, including enteric bacterial pathogens and respiratory viruses like COVID-19.

For more information, please visit: https://www.aalphabio.com/.

About A-Alpha Bio

A-Alpha Bio leverages synthetic biology and next generation sequencing tools to characterize protein-protein interactions quantitatively and in enormous throughput. The company has developed a proprietary platform technology called AlphaSeq that uses genetically engineered yeast cells to measure millions of protein-protein interaction affinities simultaneously at a library-on-library scale, generating enormous amounts of data to inform the discovery and development of potent, specific, and cross-reactive drugs. A-Alpha Bio was founded in 2017 by a team of synthetic biologists from the University of Washington’s Institute for Protein Design and Center for Synthetic Biology.

About Lumen

Lumen Bioscience is a clinical-stage biotechnology developing orally delivered antibodies and other biologics drugs for diseases of the gastrointestinal tract. This is made possible by Lumen’s unique cGMP manufacturing technology, which allows it to make orally delivered, therapeutic proteins for a small fraction of the traditional cost — cheap enough for mass-market, daily use. In addition to unlocking straightforward treatments for previously untreatable diseases, the novel approach enables faster, cheaper drug development, and the products have a better safety profile than traditional technologies. Lumen’s initial clinical programs target four high-prevalence infectious diseases, an area with well validated biological targets, significant unmet clinical need, readily available non-dilutive financing, and straightforward regulatory paths. For more information, please visit: http://www.lumen.bio.

Share article on social media or email:

Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential’s Point-of-Care COVID-19 Antibody Test


Ripple Science Logo

Ripple Science Logo

I love that Ripple is making this highly involved and complex clinical process easier and streamlined.

Ripple Science today announced their partnership with Lakeside Life Science, a diagnostic research organization that is performing a clinical study to determine antibodies using Medsential’s COVID-19 IgG/IGM Rapid Test Cassette. With 11.6 Million cases and over 500,000 deaths worldwide, the public health crisis that is COVID-19 has accelerated organizations to adopt technology like Ripple, which shorten time-to-market for biopharma solutions.

Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts, leading to valuable time and cost savings. Medsential’s test is already available for high-complexity CLIA certified labs. Lakeside’s study will be validating the test in a clinical setting. Paul Allard, COO of Lakeside Life Science, explained how Ripple helps with a very short timeline: “Ripple is streamlining the whole clinical study process for us. Our timeline for this study is incredibly short. Normally we need four to six months for study start up and 18 months to enroll patients. Our goal is to complete this entire study under a month and a half.”

Allard anticipates a follow-on study to determine how long a person has the antibodies. Lakeside, an expert in testing validation, has confirmed that Medsential’s IgM/IgG antibody test outperform antibody tests from well-known industry healthcare providers. Allard said, “In moving to a long-term study, we want high confidence in our antibody testing solution and are delighted at Medsential’s results and how easy the tests are to use.”

Lakeside is using Ripple to quickly recruit and track patients from small, underserved community centers that don’t have access to standard testing or the tools to manage clinical studies. Patients from these small centers can benefit from access to testing and are more representative of the general population.

Clinical studies are known for their complex nature beginning with recruiting patients to continual patient engagement, especially for follow-up months after the study commences. Chiao-ih Hui, COO for Medsential, is pleased that many of the study complexities are being removed. “I love that Ripple is making this highly involved and complex clinical process easier and streamlined. This will accelerate and provide a model for getting our solution to point-of-care settings and to vulnerable populations who have the most need for these solutions.”

President and CEO of Ripple Science, Peter Falzon commented, “With COVID-19, the way we conduct clinical trials has changed and there is a heightened sense of urgency. The team at Ripple Science is dedicated to enabling clinical research teams to work remotely and adopt virtual research methods, while boosting recruitment and retention.”

About Lakeside Life Science:

Lakeside Life Science was founded in January of 2015, by W. Jeffrey and Paul Allard to bring patients and communities together to advance personalized medicine through the research and development of novel diagnostic tests. Lakeside provides the resources for their clients to bring their assays from invention to FDA clearance/approval, while putting patient needs first.

About Medsential:

Medsential LLC is a US FDA registered company that develops, manufactures, and distributes a broad range of medical products to customers. Established in 2005, Medsential is an ISO certified medical device company with the capabilities to manufacture and assemble a broad range of products. Medsential has an extensive distribution channel, salesforce, engineering platform, and production team to bring quality products to global markets.

About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Science’s flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.

To learn more, please visit: https://www.ripplescience.com

Share article on social media or email:

ChronWell Launches Remote Physiologic Monitoring (RPM) Services for Gastrointestinal Physicians and Patients


News Image

“Specialists need better ways to get closer to patients, especially in these times of isolation. With RPM, we can expand our specialty protocols to better manage complex conditions like IBD without inconveniencing patients.” -Joe Rubinsztain, MD, CEO of ChronWell

ChronWell, a technology-enabled remote care management company, today announced the addition of its Remote Physiologic Monitoring (RPM) services. The goal of the new program is to closely monitor progress and improve patient adherence to treatment plans, reduce complications and help practices deliver better care while optimizing costs.

ChronWell RPM services will initially focus on patients with IBS (irritable bowel syndrome) and IBD (inflammatory bowel disease). Through digital collection tools, including wearable monitoring devices, mobile apps, secure messaging, and surveys, ChronWell’s RPM services will monitor patient health data, assess their chronic condition(s) and offer providers the ability to adjust treatment plans. Health data can include weight change, stool frequency and characteristics, appetite, fever or other indicators for change in disease and symptom progression.

“Specialists need better ways to get closer to patients, especially in these times of isolation,” said Joe Rubinsztain, MD, CEO of ChronWell. “With RPM, we can expand our specialty protocols to better manage complex conditions like IBD without inconveniencing patients.”

When using RPM to monitor patients outside the practice, providers can more appropriately assess risk and decide which patients benefit most from conservative measures or more aggressive interventions, leading to better outcomes, lower system cost and higher patient satisfaction.

ChronWell’s RPM services are part of a comprehensive care management program that also includes Chronic Care Management (CCM), Principal Care Management (PCM) and Transition Care Management (TCM) services.

To learn more about ChronWell’s Care Management program and RPM services, please visit http://www.chronwell.com/care-coordination/products/.

About ChronWell

ChronWell improves outcomes and reduces the cost of healthcare by partnering with leading specialty practices to deliver remote care management services. ChronWell is redefining how value-based care is delivered to patients suffering from chronic conditions by pairing highly skilled care teams with advanced technologies to improve patients’ lives beyond the walls of medical practice. For more information, follow us on LinkedIn or visit http://www.chronwell.com.

Share article on social media or email:

DuPont Nutrition & Biosciences Introduces CHOOZIT® BC 02 to Help Pizza Cheese Makers Expand Their Business


News Image

“As demand rises across the global pizza industry, pizza cheese makers have looked for solutions to make substantial improvement on the quality and consistency of their product,” said Annie Mornet, global product manager, Cheese Cultures at DuPont Nutrition & Biosciences.

DuPont Nutrition & Biosciences (DuPont) today announced the launch of CHOOZIT® BC 02, a new phage alternative for cheese makers looking to meet the increasing global demand for pizza cheese and meet consumers’ preference in terms of pizza cheese browning.

Part of the DuPont™ Danisco® portfolio of ingredients, the new culture joins CHOOZIT® BC 01 as a proprietary formulation designed to assist cheese makers to create added value and flexibility for their food service customers: enabling them to achieve a consistent quality pizza cheese in a wide range of ovens around the world, day after day.

The CHOOZIT® BC cultures offer key advantages, including robust processing conditions, browning control, better flexibility for pizza baking in oven conveyors, consistent cheese quality with no change in texture before shredding and a lower risk of spoilage – all in a natural, label friendly solution.

The cultures are clean label solutions to control browning, unlike many alternatives on the market that are formulated with additives. CHOOZIT® BC helps pizza cheese makers meet consumer preferences for natural products, while using less water in production, a lower volume of whey and less energy for whey drying.

Pizza cheese makers had long struggled to achieve consumers’ preferred cheese browning color using natural solutions, until last year’s successful roll-out of CHOOZIT® BC 01 in the European market. To date, CHOOZIT® BC 01 is in commercial use by a significant number of leading pizza cheese producers and in approval phases in key countries around the broader European region. These countries represent roughly 77% of the total pizza cheese produced in Europe(1).

“As demand rises across the global pizza industry, pizza cheese makers have looked for solutions to make substantial improvement on the quality and consistency of their product,” said Annie Mornet, global product manager, Cheese Cultures at DuPont Nutrition & Biosciences. “We introduced CHOOZIT® BC 01 last year and found that customers are very pleased with its unique performance. Pizza cheese makers have confirmed that CHOOZIT® BC 01 gives much better browning control for the same cheese quality, and for some particular pizza cheese manufacturing processes manufacturers have been able to use 25% less water in the pizza cheese process.”

“CHOOZIT® BC 02 takes it a step further,” she continued. “with CHOOZIT® BC 02 we present an even stronger offering to cheese producers who need to produce in industrial volumes. The cultures have been designed to provide the right acidification kinetics and proteolytic features to manage the yield and mineralization of the cheese. The metabolism of the different species allows for a better consumption of the sugars, especially galactose, throughout the process. Moreover, CHOOZIT® BC 01 and 02 are a biodiverse and alternative formulation leading to a higher robustness and limiting the phages issues.”

(1) DuPont Internal Data.

About DuPont™ Danisco®

DuPont™ Danisco® is the brand for a range of products that help provide enhanced bioprotection, an improved nutritional profile, and better taste and texture with greater cost efficiency and lower environmental impact, meeting the needs of manufacturers of food and beverages and dietary supplements. Through the work of the global network of food scientists and technologists in DuPont, the Danisco® range is supported by a uniquely broad spectrum of know-how across applications and processing.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com or http://www.biosciences.dupont.com

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/.

# # #

07/09/20

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Francis Stalder                    

+31-6 30 96 58 52                    

Francis.Stalder@dupont.com

Mariah Saerndahl                    

+1 715 210 2509

Mariah.Saerndahl@dupont.com

Share article on social media or email: